CAS 180288-69-1

Trastuzumab

Description:

Trastuzumab, commonly known by its brand name Herceptin, is a monoclonal antibody used primarily in the treatment of certain types of breast cancer and gastric cancer that overexpress the human epidermal growth factor receptor 2 (HER2). It is a recombinant DNA-derived humanized IgG1 kappa antibody, which means it is engineered to target and bind specifically to the HER2 protein on the surface of cancer cells. This binding inhibits the proliferation of these cells and promotes their destruction by the immune system. Trastuzumab is administered via intravenous infusion and is often used in combination with other chemotherapy agents to enhance therapeutic efficacy. Its mechanism of action includes blocking HER2 signaling pathways and mediating antibody-dependent cellular cytotoxicity (ADCC). The drug is associated with specific side effects, including cardiotoxicity, which necessitates careful monitoring of cardiac function during treatment. Overall, trastuzumab represents a significant advancement in targeted cancer therapy, improving outcomes for patients with HER2-positive malignancies.

Synonyms:

• Trastuzumab [USAN:INN]
• Herceptin
• Immunoglobulin G 1 (human-mouse monoclonal rhuMab HER2gamma1-chain antihuman p185(sup c-erbB2) receptor), disulfide with human-mouse monoclonal rhuMab HER2 light chain, dimer
• Unii-P188Anx8Ck
• Immunoglobulin G1, anti-(human p185neu receptor) (human-mouse monoclonal rhuMab HER2 gamma1-chain), disulfide with human-mouse monoclonal rhuMab HER2 light chain, dimer

Trastuzumab

CAS: 180288-69-1

Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2.

Purity: 97.1% (SDS-PAGE); 99.2% (SEC-HPLC) - SDS-PAGE: 97.1%；SEC-HPLC: 99.2%

Color and Shape: Liquid

Molecular weight: Approximately 145.53 kDa

Ref: TM-T9912

Trastuzumab - 20mg/ml in PBS

CAS: 180288-69-1

Trastuzumab is a humanised immunoglobulin G1 monoclonal antibody against human epidermal growth factor receptor 2 (HER2), used in breast cancer treatments. Some potential extracellular and intracellular antitumor mechanisms of trastuzumab have been proposed, including activation of antibody-dependent cellular cytotoxicity, inhibition of extracellular domain cleavage, abrogation of intracellular signalling, reduction of angiogenesis and decreased DNA repair that result in tumour cell stasis and/or death. Its drug conjugate, trastuzumab deruxtecan (T-DXd), is used in the clinical therapy for pretreated HER2-mutant non-small cell lung cancer (NSCLC).

Purity: Min. 95 Area-%

Color and Shape: Clear Liquid

Ref: 3D-FT65040

Trastuzumab - 20mg/ml in Histidine buffer (lyophilised powder)

CAS: 180288-69-1

Trastuzumab is a humanised immunoglobulin G1 monoclonal antibody against human epidermal growth factor receptor 2 (HER2), used in breast cancer treatments. Some potential extracellular and intracellular antitumor mechanisms of trastuzumab have been proposed, including activation of antibody-dependent cellular cytotoxicity, inhibition of extracellular domain cleavage, abrogation of intracellular signalling, reduction of angiogenesis and decreased DNA repair that result in tumour cell stasis and/or death. Its drug conjugate, trastuzumab deruxtecan (T-DXd), is used in the clinical therapy for pretreated HER2-mutant non-small cell lung cancer (NSCLC).

Ref: 3D-BT184541

Trastuzumab

CAS: 180288-69-1

Ref: 4Z-T-400004